Volatile Stocks: Echo Therapeutics Inc (NASDAQ:ECTE), Merit Medical Systems (NASDAQ:MMSI), Applied Genetic Technologies Corp (NASDAQ:AGTC), BioLife Solutions Inc (NASDAQ:BLFS), Theravance Biopharma (NASDAQ:TBPH)

On 21 JUNE Echo Therapeutics Inc (NASDAQ:ECTE) reported ($0.23) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.31) by $0.08. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Analysts expect that Echo Therapeutics will post $-0.90 EPS for the current fiscal year. Echo Therapeutics Inc (NASDAQ:ECTE) on last trading day company shares ended up $2.26. Analysts mean target price for the company is $3.50. Echo Therapeutics Inc (NASDAQ:ECTE) distance from 50-day simple moving average (SMA50) is -2.72%.

On 24 JUNE Merit Medical Systems, Inc. (NASDAQ:MMSI) reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by $0.01. The company had revenue of $119.20 million for the quarter, compared to the consensus estimate of $114.54 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts predict that Merit Medical Systems will post $0.76 earnings per share for the current fiscal year. Merit Medical Systems, Inc. (NASDAQ:MMSI) shares fell -0.66% in last trading session and ended the day on $15.10. MMSI Gross Margin is 43.80% and its return on assets is 2.60%. Merit Medical Systems, Inc. (NASDAQ:MMSI) quarterly performance is 5.59%.

Applied Genetic Technologies Corp (NASDAQ:AGTC) announced that it has appointed David R. Guyer, MD, and Ivana Magovcevic-Liebisch, PhD, JD, to the company’s Board of Directors. Applied Genetic Technologies Corp (NASDAQ:AGTC) shares moved down -8.26% in last trading session and was closed at $23.10, while trading in range of $22.57 – $25.30. Applied Genetic Technologies Corp (NASDAQ:AGTC) year to date (YTD) performance is 56.50%.

On 16 JUNE BioLife Solutions Inc (NASDAQ:BLFS) announced that Nice, France-based TxCell (Euronext Paris: TXCL) a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, has adopted BioLife’s CryoStor clinical grade cell freezing media for use in their European phase IIb clinical trial of Ovasave immunotherapy in refractory Crohn’s Disease, which is planned to start in the second half of 2014. BioLife Solutions Inc (NASDAQ:BLFS) ended the last trading day at $2.28. Company weekly volatility is calculated as 11.05% and price to cash ratio as 2.14. BioLife Solutions Inc (NASDAQ:BLFS) showed a positive weekly performance of 8.57%.

On 3 JUNE Theravance Biopharma Inc (NASDAQ:TBPH) and Theravance have announced the completion of the separation of Theravance Biopharma, the research and development-based biopharmaceutical business, from Theravance. to form two, independent, publicly traded companies with differing business objectives and opportunities, via a dividend distribution of Theravance Biopharma shares to Theravance stockholders. Theravance Biopharma Inc (NASDAQ:TBPH) weekly performance is -8.57%. On last trading day company shares ended up $31.88. Theravance Biopharma Inc (NASDAQ:TBPH) distance from 50-day simple moving average (SMA50) is 18.54%.